The US Court of Appeals for the Federal Circuit has ruled that Acetris Health LLC’s pharmaceuticals, which are made in New Jersey with ingredients from India, should have been contract eligible as “U.S.-made end products.” Morgan Lewis represented Acetris in the case.
Read the full Bloomberg Law article >>
Subscription may be required.